XML 10 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
May 02, 2025
Jun. 28, 2024
Document Information [Line Items]      
Document Type 10-K/A    
Document Annual Report true    
Amendment Flag true    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Registrant Name IN8BIO, INC.    
Entity Central Index Key 0001740279    
Entity Tax Identification Number 82-5462585    
Current Fiscal Year End Date --12-31    
Entity Current Reporting Status Yes    
Entity Filer Category Non-accelerated Filer    
Entity File Number 001-39692    
Entity Shell Company false    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
ICFR Auditor Attestation Flag false    
Entity Small Business true    
Entity Interactive Data Current Yes    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 350 5th Avenue    
Entity Address, Address Line Two Suite 5330    
Entity Address, City or Town New York    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10118    
City Area Code 646    
Local Phone Number 600-6438    
Trading Symbol INAB    
Title of 12(b) Security Common Stock, $0.0001 par value per share    
Document Financial Statement Error Correction [Flag] false    
Document Transition Report false    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
Entity Public Float     $ 29.0
Amendment Description EXPLANATORY NOTE IN8bio, Inc. (the “Company”) is filing this Amendment No. 1 to its Annual Report on Form 10-K (this “Amendment”), originally filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2025 (the “Initial Filing”). This Amendment is being filed solely to correct the exhibit list contained in Item 15 of Part IV of the Initial Filing. In connection with the filing of this Amendment, the Company is including new certifications of its principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Accordingly, Item 15 of Part IV of the Initial Filing has also been amended to reflect the filing of the new certifications. Since no new financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. In addition, because no financial statements are contained within this Amendment, the Company is not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Except as contained herein, this Amendment does not modify or update disclosures contained in the Initial Filing. This Amendment should be read in conjunction with the Company’s other filings made with the SEC subsequent to the date of the Initial Filing. In this Amendment, unless the context requires otherwise, all references to “we,” “our,” “us,” “IN8bio” and the “Company” refer to IN8bio, Inc.    
Documents Incorporated by Reference [Text Block]
DOCUMENTS INCORPORATED BY REFERENCE
None.
   
Auditor Name CohnReznick LLP    
Auditor Firm ID 596    
Auditor Location Tysons, Virgina    
Security Exchange Name NASDAQ    
Entity Common Stock, Shares Outstanding   90,771,944